Price
Target price
€24.07
€24.07
0.920%
0.22
0.920%
-
04.06.26 / Tradegate
WKN: A2PLU4 / Name: Capricor / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Capricor Therapeutics Inc Stock
Capricor Therapeutics Inc gained 0.920% compared to yesterday.
Our community identified positive and negative aspects for Capricor Therapeutics Inc stock for the coming years. 0 users see the criterium "Return on equity" as a plus for the Capricor Therapeutics Inc stock. On the other hand our users think that "Return on equity" could be a problem in the future.
Pros and Cons of Capricor Therapeutics Inc in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Capricor Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Capricor Therapeutics Inc | 0.920% | -3.450% | -15.957% | 122.870% | -6.160% | 464.361% | 656.918% |
| Heron Therapeutics Inc. | 13.110% | -47.518% | -60.763% | -76.689% | -63.088% | -60.838% | -96.309% |
| Evolus Inc | -2.640% | -9.461% | 8.214% | -40.329% | -6.936% | -37.767% | -43.330% |
| Rhythm Pharmaceuticals | -1.320% | -9.434% | -1.370% | 27.434% | -22.995% | 339.024% | 373.684% |
News
Capricor Therapeutics Q1 Earnings Call Highlights
Capricor Therapeutics (NASDAQ:CAPR) said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review
Capricor's Insider Just Sold Big — Her Options Tell the rest of the Story
Karen Krasney, EVP, General Counsel of Capricor Therapeutics (NASDAQ:CAPR), exercised 25,000 options for common stock and immediately sold the resulting shares for a transaction value of
Here's Why This Biotechnology Skyrocketed by 439% in December
Capricor Therapeutics (NASDAQ: CAPR) stock rose an incredible 439.4% in December, according to data provided by S&P Global Market Intelligence. The move followed the company's announcement of